Far fewer people who could benefit from statins actually take the cholesterol-lowering drugs now. Many who start taking them stop. The long list of side effects, detailed in fine print on package inserts and discussed in exam rooms over the years, pose barriers to many patients, doctors say.
A new meta-analysis hopes to set the record straight on one of the most widely used, low-cost doses of cardiovascular disease prevention available.
STAT Pharma: The science and business of new drug development
Leave a Reply